Storage stability and delivery potential of cytochalasin B induced membrane vesicles.
Cytochalasin B-induced membrane vesicles
Extracellular vesicles
Lyophilization
Mesenchymal stem cells
Microvesicles
Storage
Journal
Biotechnology reports (Amsterdam, Netherlands)
ISSN: 2215-017X
Titre abrégé: Biotechnol Rep (Amst)
Pays: Netherlands
ID NLM: 101637426
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
11
11
2020
revised:
03
04
2021
accepted:
05
04
2021
entrez:
17
5
2021
pubmed:
18
5
2021
medline:
18
5
2021
Statut:
epublish
Résumé
Cell-free therapies based on extracellular vesicles (EVs) derived from mesenchymal stem cells (MSCs) are considered as a promising tool for stimulating regeneration and immunomodulation. The need to develop a practical approach for large-scale production of vesicles with homogenous content led to the implementation of cytochalasin B-induced to induce microvesicles (CIMVs) biogenesis. CIMVs mimic natural EVs in size and composition of the surrounding cytoplasmic membrane. Previously we observed that MSC derived CIMVs demonstrate the same therapeutic angiogenic and immunomodulatory activity as the parental MSCs, making them a potentially scalable cell-free therapeutic option. However, little is known about their storage stability and delivery potential. We determined that different storage conditions alter the protein concentration within the solution used to store CIMVs over time, this concided with a decrease in the amount of CIMVs due to gradual degradation. We established that freezing and storage CIMVs in saline at -20 °C reduces degredation and prolongs their shelf life. Additionally, we found that freeze-thawing preserved the CIMVs morphology better than freeze drying and subsequent rehydration which resulted in aggregation of CIMVs. Collectively our data demonstrates for the first time, that the most optimal method of CIMVs storage is freezing at -20 °C, to preserve the CIMVs in the maximum quantity and quality with retention of effective delivery. These findings will benefit the formation of standardized protocols for the use of CIMVs for both basic research and clinical application.
Identifiants
pubmed: 33996522
doi: 10.1016/j.btre.2021.e00616
pii: S2215-017X(21)00032-1
pmc: PMC8090994
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e00616Informations de copyright
© 2021 The Authors. Published by Elsevier B.V.
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Biomed Res Int. 2018 Apr 8;2018:7053623
pubmed: 29850552
Stem Cell Rev Rep. 2015 Feb;11(1):150-60
pubmed: 25091427
Kidney Int. 2007 Aug;72(4):430-41
pubmed: 17507906
J Cell Biol. 2010 Sep 20;190(6):1079-91
pubmed: 20837771
Cell Commun Signal. 2014 Oct 14;12:64
pubmed: 25311367
J Am Chem Soc. 2005 Mar 9;127(9):2908-12
pubmed: 15740126
J Neurooncol. 2013 May;113(1):1-11
pubmed: 23456661
Leukemia. 2006 May;20(5):847-56
pubmed: 16453000
Cardiovasc Res. 2014 Sep 1;103(4):530-41
pubmed: 25016614
Cells. 2019 Dec 30;9(1):
pubmed: 31906012
J Transl Med. 2015 Feb 01;13:49
pubmed: 25638205
Nat Cell Biol. 2012 Oct;14(10):1036-45
pubmed: 22983114
Leukemia. 2006 Sep;20(9):1487-95
pubmed: 16791265
Stem Cells Dev. 2014 Jul 15;23(14):1625-35
pubmed: 24641099
Cell. 2012 Dec 21;151(7):1542-56
pubmed: 23260141
PLoS One. 2010 Jul 27;5(7):e11803
pubmed: 20668554
Stem Cells Dev. 2015 Jul 15;24(14):1635-47
pubmed: 25867197
J Trauma Acute Care Surg. 2014 Apr;76(4):991-7
pubmed: 24662862
Front Immunol. 2019 Nov 15;10:2663
pubmed: 31849929
Nano Lett. 2011 May 11;11(5):2152-6
pubmed: 21486057
Curr Mol Biol Rep. 2016;2:48-55
pubmed: 27429899
Cell Stem Cell. 2012 Jul 6;11(1):127-35
pubmed: 22770246
Cancer Res. 2011 Aug 1;71(15):5346-56
pubmed: 21670082
PLoS One. 2014 Feb 18;9(2):e88685
pubmed: 24558412
Nat Cell Biol. 2007 Jun;9(6):654-9
pubmed: 17486113
Oncotarget. 2017 Jul 31;8(41):70496-70507
pubmed: 29050297
J Extracell Vesicles. 2014 Dec 22;3:25465
pubmed: 25536933
Stem Cells Int. 2016;2016:1073140
pubmed: 26649044
Stem Cells. 2012 Jul;30(7):1556-64
pubmed: 22605481
J Mol Med (Berl). 2014 Apr;92(4):387-97
pubmed: 24337504
EMBO Mol Med. 2011 Jul;3(7):398-409
pubmed: 21591261
In Vitro Cell Dev Biol Anim. 2018 Jun;54(6):423-429
pubmed: 29748909
PLoS One. 2012;7(3):e33115
pubmed: 22431999
Nat Commun. 2014 Dec 04;5:5649
pubmed: 25472772
Sci Rep. 2013;3:1197
pubmed: 23378928
ACS Appl Mater Interfaces. 2015 Aug 26;7(33):18628-37
pubmed: 26262951